Lineage Cell Therapeutics NYSEAMERICAN: LCTX outlined progress across its cell-therapy pipeline duri

Lineage Cell Therapeutics, Inc. (LCTX) Q2 2026 Earnings Call Transcript

Lineage Cell (LCTX) came out with a quarterly loss of $0.03 per share in line with the Zacks Consens

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Q2 2026 Earnings Release.

Lineage Cell Therapeutics NYSEAMERICAN: LCTX used a conference call to outline its manufacturing str

Lineage Cell Therapeutics, Inc. (LCTX) Discusses COR1 Cell Transplant Program and Manufacturing Stra

Company Will Host Conference Call Today at 4:30 PM ET / 1:30 PM PTCOR1 Aims to Provide an "Off t

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc

On Tuesday, Lineage Cell Therapeutics (AMEX:LCTX) discussed first-quarter financial results during i

Lineage Cell Therapeutics NYSEAMERICAN: LCTX reported first-quarter 2026 results and used its earnin

Lineage Cell Therapeutics, Inc. (LCTX) Q1 2026 Earnings Call Transcript

Lineage Cell (LCTX) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Est

Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.03) per share which missed th

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc

AVAI, LCTX, OCGN, VRTX, and LGVN Advance Cell-Based and Gene-Therapy Approaches to Age-Related Disea

US stock futures up, Nasdaq 100 gains 100 pts. Service Properties Trust (SVC) drops 4% in pre-market

Defender Capital LLC. bought a new stake in shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:

HC Wainwright & Co. analyst Joseph Pantginis reiterates Lineage Cell Therapeutics (AMEX:LCTX)

New Internally-Developed and Wholly-Owned Asset Benefits From Existing Ophthalmology and Manufacturi

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc

$100,000,000 Common SharesPreferred SharesDebt SecuritiesWarrants From time to time, we may offer up

Other Events.On March 11, 2026, Lineage Cell Therapeutics, Inc. (the "Company") filed with t

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) used its quarterly conference call to highlight a long

D. Boral Capital analyst Jason Kolbert maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy

Lineage Cell Therapeutics, Inc. (LCTX) Q4 2025 Earnings Call Transcript

Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly earnings of $0.00 per share which beat the

D. Boral Capital analyst Jason Kolbert maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy

HC Wainwright & Co. analyst Joseph Pantginis maintains Lineage Cell Therapeutics (AMEX:LCTX)

On November 12, 2025, Lineage Cell Therapeutics, Inc. (the "Company") sold 12,000,000 common

Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.13) per share which missed th

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology compa

D. Boral Capital analyst Jason Kolbert maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy

Three-year term intended to advance preclinical development of ReSonanceUp to $12 million of develop

D. Boral Capital analyst Jason Kolbert maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy

Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.07) per share which missed th

Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.13) per share which missed th